Zepbound Clinical Trial Findings

Order byBest matchMost fresh

Zepbound beats Wegovy for weight loss

Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

· 2d · on MSN

Becker's Hospital Review · 1d

Zepbound beats Wegovy for weight loss: Study

EconoTimes · 2d

Eli Lilly’s Zepbound Outperforms Wegovy in Weight Loss Head-to-Head Trial

What is the most effective weight loss drug?

drug maker Eli Lilly put its own weight loss drug Zepbound against the popular drug Wegovy, and Zepbound outperformed, causing 6% more weight loss than its competitor.

· 1d

New study compares Wegovy and Zepbound for the first time

· 2d

Study finds Zepbound may help people lose more weight than Wegovy

Why patients are being forced to switch to a 2nd-choice obesity drug

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of insurance-imposed limits that disrupt treatment.

New Atlas1d

Dual-target weight-loss drug is 47% more effective than its rival

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference. And one clearly comes out on top.